# CE mark for molecular Dx system, 8/16

written by CAP TODAY
August 17, 2016

August 2016—GenMark Diagnostics received the CE mark for its ePlex Instrument System and ePlex Respiratory Pathogen (RP) Panel. The panel detects 20 viral and three bacterial targets in nasopharyngeal specimens.




---

# Qiagen collaborations, 8/16

written by CAP TODAY
August 17, 2016

August 2016—Qiagen has entered into a licensing and co-development agreement with Munich-based Therawis Diagnostics to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict the effectiveness of anthracycline treatment in triple-negative and other high-risk breast cancer patients.




---

# Cryostat, 8/16

written by CAP TODAY
August 17, 2016

August 2016—The Tissue-Tek Cryo3 Flex Cryostat, from Sakura Finetek USA, produces sections from 1 to 99 µm using a temperature-controlled blade holder and a 3-D precision chuck to accurately align the block face to the blade, reducing user's trimming time and preserving specimens.



---

# For certain thyroid lesions, the shift is on

written by CAP TODAY
August 17, 2016

July 2016—Time was running out for Yuri Nikiforov, MD, PhD, vice chair for molecular pathology and division director of molecular and genomic pathology, University of Pittsburgh Medical Center. For nearly a year he had been working to assemble an international group of experts—pathologists, endocrinologists, a surgeon, and, unusually, a psychiatrist and a patient advocate—to discuss that most vexing of thyroid tumors, encapsulated follicular variant of papillary thyroid carcinoma, or EFVPTC.



---

# Laboratory 2.0: Changing the conversation

written by CAP TODAY
August 17, 2016

July 2016—Bundled payments, physician employment, and unconventional competitors are cannibalizing the volume-based business model that for decades has defined laboratory medicine. And labs have little room within their customary confines—the three percent of health system spending they directly account for—to play a central role in American medicine's transformation.

---

# Making the best of PD-L1 IHC testing

written by CAP TODAY
August 17, 2016

July 2016—When Keith Kerr, MB ChB, describes the ideal biomarker, he isn't hesitant about what pathologists and clinicians need. "Ideally, the biomarker would always be correct. It would be easy and practical to measure. It would either be present or absent, with no gray zone or doubt.



---

# In *C. diff* and cardiac care, lab steps up decision support

written by CAP TODAY
August 17, 2016

July 2016—What's the one way to win friends and influence people? If you're Eugenio H. Zabaleta, PhD, the answer is simple: Reduce the number of stool samples nurses have to collect. A few years ago, Dr. Zabaleta, clinical chemist at OhioHealth Mans-field Hospital, introduced a clinical testing algorithm for C. difficile that cut the number of stool samples by almost 50 percent. "And the nurses are loooving me for it," he says happily. "The joke is, when nursing and lab work together, there is literally less crap for everybody."

---

# From the President's Desk: Keeping your eye on the ball—and not

written by CAP TODAY
August 17, 2016

July 2016—I love to read and I like to watch a good baseball game. Sometimes I can actually use one to enhance the other. No, this is not leading to a discussion on Bull Durham and how life is defined by baseball or Field of Dreams and the logic of build it and they will come.



---

# A rare case of Diamond Blackfan anemia: identifying the causative mutation using NGS

written by CAP TODAY
August 17, 2016

July 2016—Diamond Blackfan anemia is a rare, inherited bone marrow failure syndrome manifesting as marked red cell aplasia and variable congenital anomalies. We report here a case of Diamond Blackfan anemia, which underscores the role of an integrated diagnostic workflow including hematopathologic evaluation and next-generation sequencing for establishing the diagnosis and potential management of rare, inherited bone marrow failure syndromes.

# Shorts on Standards: Update on the frontier of NGS, 7/16

written by CAP TODAY
August 17, 2016

July 2016—Next-generation sequencing has continued to deliver on its promises and potential in the diagnostic arena. However, as with any emerging and evolving technology, the medical and scientific community faces the challenge of assessing the implications and demonstrating definitive clinical uses of its expanding capabilities, especially in the context of medical efficacy, clinical utility, and cost efficiency.

©2026 CAP TODAY, all rights reserved.